Bobbi Brockmann - ImmuCell VP of Sales and Marketing
| ICCC Stock | USD 5.03 0.01 0.20% |
VP
Ms. Bobbi Jo Brockmann is Vice President Sales and Marketing, Director of the Company. She served as a Director of the Company from March 2017 to September 2017 and from January 2018 to the present. She was promoted to Vice President of Sales and Marketing in February 2015. She joined the Company as Director of Sales and Marketing in January 2010. Prior to that, she had been employed as Director of Sales since May 2008 and Sales Manager from February 2004 to April 2008 at APC, Inc. of Ankeny, Iowa, a developer and marketer of functional protein products for animal health and nutrition. Prior to that, she held other sales and marketing positions at APC, W G Marketing Company, Inc. of Ames, Iowa, The Council for Agricultural Science and Technology of Ames, Iowa and Meyocks Group Advertising of West Des Moines, Iowa after graduating from Iowa State University. since 2018.
| Age | 47 |
| Tenure | 6 years |
| Address | 56 Evergreen Drive, Portland, ME, United States, 04103 |
| Phone | 207 878 2770 |
| Web | https://immucell.com |
ImmuCell Management Efficiency
The company has return on total asset (ROA) of (0.0736) % which means that it has lost $0.0736 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2086) %, meaning that it created substantial loss on money invested by shareholders. ImmuCell's management efficiency ratios could be used to measure how well ImmuCell manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.05. In addition to that, Return On Capital Employed is expected to decline to -0.05. At present, ImmuCell's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 16.9 M, whereas Non Currrent Assets Other are forecasted to decline to about 65.5 K.Similar Executives
| Found 1 records | VP Age | ||
| Francis CPA | Larimar Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.0736 |
ImmuCell Leadership Team
Elected by the shareholders, the ImmuCell's board of directors comprises two types of representatives: ImmuCell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmuCell. The board's role is to monitor ImmuCell's management team and ensure that shareholders' interests are well served. ImmuCell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmuCell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Tomsche, Independent Chairman of the Board | ||
| Elizabeth Williams, Vice President - Manufacturing Operations | ||
| Elizabeth Toothaker, Director Administration | ||
| Linda Rhodes, Independent Director | ||
| Michael Brigham, CEO and President CFO, Treasurer, Secretary and Director | ||
| John Zinckgraf, Director Development | ||
| Steven Rosgen, Independent Director | ||
| Joseph Crabb, Chief Scientific Officer, VP and Director | ||
| Bobbi Brockmann, VP of Sales and Marketing | ||
| Paul Wainman, Director | ||
| Gustavo Scaffa, Director Quality | ||
| Jonathan Rothschild, Independent Director | ||
| David Cunningham, Independent Director |
ImmuCell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ImmuCell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.0736 | ||||
| Profit Margin | (0.33) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 54.7 M | ||||
| Shares Outstanding | 7.75 M | ||||
| Shares Owned By Insiders | 28.04 % | ||||
| Shares Owned By Institutions | 13.48 % | ||||
| Number Of Shares Shorted | 6.12 K | ||||
| Price To Earning | 195.00 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ImmuCell in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ImmuCell's short interest history, or implied volatility extrapolated from ImmuCell options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.Note that the ImmuCell information on this page should be used as a complementary analysis to other ImmuCell's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for ImmuCell Stock analysis
When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is ImmuCell's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.75) | Revenue Per Share 2.255 | Quarterly Revenue Growth 0.303 | Return On Assets (0.07) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.